

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 12b-25**

**NOTIFICATION OF LATE FILING**

Commission File Number: **000-54717**

(Check One):     Form 10-K     Form 20-F     Form 11-K     Form 10-Q     Form 10-D  
                   Form N-  
                  SAR  
                  For Period  
                  Ended: \_\_\_\_\_

- Transition Report on Form 10-K
- Transition Report on Form 20-F
- Transition Report on Form 11-K
- Transition Report on Form 10-Q
- Transition Report on Form N-SAR

For the Transition Period Ended: December 31, 2015

*Read Instruction (on back page) Before Preparing Form. Please Print or Type.*  
**Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.**

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I — REGISTRANT INFORMATION**

**BIOTRICITY INC.**

Full Name of Registrant

Former Name if Applicable

**75 International Blvd., Suite 300**

Address of Principal Executive Office (*Street and Number*)

**Toronto, ON M9W 6L9**

City, State and Zip Code

## **PART II — RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

## **PART III — NARRATIVE**

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Form 10-K for the four month transition period ended December 31, 2015, and the audited financial statements for the fiscal year ended December 31, 2015 of iMedical Innovations Inc., the Registrant's indirect subsidiary as of February 2, 2016, will not be submitted by the deadline without unreasonable effort or expense. The Registrant had unanticipated delays in the collection and compilation of certain information required to be included in the 10-K. The Registrant will file the 10-K on or before the fifteenth calendar day following the prescribed due date.

(Attach extra Sheets if Needed)

## PART IV — OTHER INFORMATION

- (1) Name and telephone number of person to contact in regard to this notification

Waqas Al-Siddiq	416	214-3678
(Name)	(Area Code)	(Telephone Number)

- (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

Yes  No

- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes  No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

**Biotricity Inc.**

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date      March 31, 2016

By      /s/ WAQAAS AL-SIDDIQ  
Waqaas Al-Siddiq, CEO